Galapagos NV (GLPG)
NASDAQ: GLPG · Real-Time Price · USD
34.14
+0.21 (0.62%)
Feb 11, 2026, 2:51 PM EST - Market open
Galapagos NV Revenue
Galapagos NV had revenue of 71.16M EUR in the quarter ending September 30, 2025, with 18.90% growth. This brings the company's revenue in the last twelve months to 286.92M, up 10.31% year-over-year. In the year 2024, Galapagos NV had annual revenue of 275.65M with 14.99% growth.
Revenue (ttm)
286.92M EUR
Revenue Growth
+10.31%
P/S Ratio
6.60
Revenue / Employee
514,195 EUR
Employees
558
Market Cap
2.22B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 275.65M | 35.93M | 14.99% |
| Dec 31, 2023 | 239.72M | -1.53M | -0.63% |
| Dec 31, 2022 | 241.25M | 6.87M | 2.93% |
| Dec 31, 2021 | 234.38M | -243.67M | -50.97% |
| Dec 31, 2020 | 478.05M | -356.85M | -42.74% |
| Dec 31, 2019 | 834.90M | 556.24M | 199.61% |
| Dec 31, 2018 | 278.67M | 151.58M | 119.27% |
| Dec 31, 2017 | 127.09M | -2.43M | -1.88% |
| Dec 31, 2016 | 129.52M | 89.96M | 227.37% |
| Dec 31, 2015 | 39.56M | -29.81M | -42.97% |
| Dec 31, 2014 | 69.37M | 69.29M | 90,429.20% |
| Dec 31, 2013 | 76.63K | -136.19M | -99.94% |
| Dec 31, 2012 | 136.27M | 42.80M | 45.79% |
| Dec 31, 2011 | 93.47M | -20.67M | -18.11% |
| Dec 31, 2010 | 114.14M | 21.05M | 22.62% |
| Dec 31, 2009 | 93.09M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Harmony Biosciences Holdings | 825.94M |
| Telix Pharmaceuticals | 664.23M |
| Ultragenyx Pharmaceutical | 630.60M |
| Zai Lab | 441.63M |
| Ascentage Pharma Group International | 54.52M |
| Recursion Pharmaceuticals | 43.69M |
| Mesoblast | 17.20M |
| Dianthus Therapeutics | 3.08M |
GLPG News
- 5 weeks ago - Galapagos Announces Board Decision to Initiate Wind-Down of Cell Therapy Activities - GlobeNewsWire
- 7 weeks ago - Galapagos: Pivoting From Clinical Risk To Strategic Capital Allocation - Seeking Alpha
- 2 months ago - Galapagos Presented New ATALANTA-1 Cell Therapy Data in MCL at ASH 2025 - GlobeNewsWire
- 2 months ago - Galapagos Receives Transparency Notifications from Bank of America - GlobeNewsWire
- 3 months ago - Galapagos NV (GLPG) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Galapagos to Present New Data from Cell Therapy Program at ASH 2025 - GlobeNewsWire
- 3 months ago - Galapagos to Present In Vitro Data at ACR Convergence 2025 Suggesting Differentiation of GLPG3667 from Other TYK2 Inhibitors - GlobeNewsWire
- 4 months ago - Biotech firm Galapagos to wind down cell therapy business - Reuters